Featured
White Papers
Process development and analytical development are integral parts of gene therapy manufacturing. This whitepaper explores the analytical and development approaches needed to create a path to success in the clinic and beyond.
Antibody-drug conjugates (ADCs) are revolutionizing the field of targeted cancer therapies, but their development and manufacturing processes pose significant complexities that must be addressed.
Pfizer experts are ready to help meet your complex OSD needs from our site in Ascoli, Italy.
The antibody therapeutic space has rapidly evolved over the last 30 years.
To ensure the safe, successful delivery of your innovative therapeutic to the patients who need it more, time is life, and expertise is key.
To meet the demands of the oral solid dosage (OSD) market, new techniques and technologies have emerged.
This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.
In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.
Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.
Pfizer CentreOne’s sterile injectables experts discuss how a small or medium sized biotech or pharma company can benefit from the experience and assistance provided by a CDMO for their sterile injectable project.
Medical science is continuously searching for better ways to administer drugs into the body and to maximise the therapeutic effectiveness of the drugs given.
Development of novel small molecule active pharmaceutical ingredients (APIs) is increasingly turned over to outsourced partners who have become the primary drivers of the product’s overall development and go-to-market strategy.
